Astellas Pharma’s Xtandi gets reimbursement recommendation in US
Astellas Pharma’s Xtandi (fixing: enzalutamide), the tenderfoot medication that extended sign for metastatic hormone-sensitive prostate disease (mHSPC), scored the U.K’s.
Read moreAstellas Pharma’s Xtandi (fixing: enzalutamide), the tenderfoot medication that extended sign for metastatic hormone-sensitive prostate disease (mHSPC), scored the U.K’s.
Read more